Table 3 Associations of the patient characteristics with the OS (Cox proportional hazards model)
HR | P | ||
|---|---|---|---|
EGFR mutation | Exon 19 del | 0.40 (0.21–0.78) | 0.007 |
Exon 21 L858R | 1.00 | ||
Uncommon mutation | 0.83 (0.32–2.13) | 0.699 | |
PS | 0–1 | 035 (0.18–0.67) | 0.002 |
≥2 | 1.00 | ||
LDH (U/L) | <200 | 0.43 (0.23–0.82) | 0.011 |
≥200 | 1.00 | ||
History of surgery | Yes | 0.77 (0.33–1.83) | 0.557 |
No | 1.00 | ||
Brain metastasis | Yes (with local therapy) | 0.18 (0.05–0.65) | 0.008 |
Yes (without local therapy) | 1.00 | ||
No | 0.68 (0.28–1.62) | 0.384 | |
First-line TKI used | 1st-generation TKIs | 1.00 | |
Afatinib | 0.50 (0.21–1.20) | 0.120 | |
Osimertinib | 0.37 (0.10–1.29) | 0.119 | |
Sequential therapy with TKIs | Osimertinib | 0.25 (0.11–0.60) | 0.002 |
1st/2nd-generation TKIs | 1.01 (0.44–2.33) | 0.973 | |
None | 1.00 |